查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1922954

全磁浮左心室輔助裝置市場：按電源、患者年齡、應用、最終用戶和通路－2026-2032年全球預測

Fully MagLev Left Ventricular Assist Device Market by Power Source, Patient Age, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全磁浮左心室輔助裝置市場預計到 2025 年價值 15.9 億美元，到 2026 年將成長到 17.8 億美元，到 2032 年達到 32.7 億美元，複合年成長率為 10.83%。

關鍵市場統計數據
基準年 2025 15.9億美元
預計年份：2026年 17.8億美元
預測年份 2032 32.7億美元
複合年成長率 (%) 10.83%

權威的介紹概述了全磁浮左心室輔助裝置的臨床和技術進步及其對醫療保健服務的影響。

全磁浮左心室輔助裝置的出現標誌著晚期心臟衰竭治療領域的一個重要轉折點，它將機械工程的精準性與臨床上對耐用性和血液相容性的迫切需求完美結合。這些新一代幫浦最大限度地減少了機械接觸，降低了血液剪切應力，從而降低了裝置相關溶血、血栓症和神經系統不利事件的發生率。臨床醫生正日益重視這些系統，不僅將其視為一種過渡治療策略，而且將其視為在無法立即進行心臟移植時的持久替代方案。

說明了正在重塑磁浮左心室輔助裝置（LVAD）治療的採用、採購和長期管理的融合技術、監管和臨床變革。

由於技術、監管和臨床實踐的動態發展，全磁浮左心室輔助裝置（LVAD）的模式正在迅速變化。在技​​術層面，先進磁浮技術、改良的血液相容性表面以及嵌入式診斷功能的整合，正在提升LVAD的治療效果，從而延長其功能壽命並降低併發症率。在臨床層面，隨著心臟團隊在移植過渡治療和根治性治療中對這些系統的使用信心不斷增強，患者選擇標準也在不斷演變，擴大了適用患者群體，並重新定義了長期照護路徑。

對2025年美國關稅變化將給全磁浮裝置（LVAD）的開發商和供應商帶來的供應鏈、採購和供應方面的複雜性進行深入分析

美國關稅及貿易政策調整（至2025年）正為醫療設備採購、零件供應和跨境分銷策略帶來新的變數。依賴全球供應鏈採購精密磁鐵、電力電子元件和特殊聚合物的製造商正面臨到岸成本波動加劇的局面，這影響著零件供應、庫存緩衝和製造地的決策。這些趨勢促使醫療器材開發商重新評估供應商多元化和近岸外包方案，以滿足專案進度和品質標準。

基於細分市場的詳細洞察，解釋了應用、分銷模式、患者人口統計特徵、電源架構和最終用戶畫像如何決定採用路徑和專案設計。

從成熟的臨床和商業性觀點分析全磁浮裝置（LVAD）市場，可以發現各細分市場的發展趨勢存在差異，呈現不同的應用路徑和使用模式。根據應用領域，該市場可分為過渡性治療、移植過渡和終末治療。每種應用領域對設備生命週期預期、監測方案和臨床結果的重點各不相同，其中輔助性治療側重於短期可靠性，而終末治療側則側重於長期耐用性和患者生活品質。根據分銷管道，該市場可分為直銷和分銷商銷售。直銷模式有利於密切的臨床合作和術後支持，而經銷商通路則有助於擴大地域覆蓋範圍和建立本地服務網路。

全面的區域分析揭示了醫療保健基礎設施、報銷制度和臨床能力方面的差異將如何影響世界各地採用磁浮左心室輔助裝置 (LVAD) 解決方案的情況。

區域差異將影響全磁浮（LVAD）解決方案的臨床實踐模式、監管參與和商業性部署。在美洲地區，某些司法管轄區的先進心臟病計畫和整合的支付系統正在推動早期臨床應用和長期療效數據的積累，使卓越中心能夠不斷改進術後護理模式。相較之下，在歐洲、中東和非洲地區（EMEA），區域醫療保健系統結構導致報銷途徑各異，因此需要製定個人化的市場進入策略，充分考慮各國的衛生技術評估（HTA）流程、醫院採購慣例和區域醫療中心的能力。

從公司層面深入洞察技術領先地位、策略夥伴關係關係和強大的售後能力如何決定磁浮裝置 (LVAD) 開發中的競爭優勢

全磁浮裝置（LVAD）領域的競爭格局以深厚的技術專長、戰略夥伴關係以及對上市後證據產生的重點投入為特徵。成熟的醫療設備製造商和專注於此領域的Start-Ups都在優先考慮對磁性技術、生物材料和整合診斷進行持續的研發投入，以確保設備的長期可靠性和臨床醫生的信心。同時，各公司正在加強與學術機構、契約製造和數位醫療服務提供者的合作，以加速證據產生並將遠端監測整合到標準治療方案中。

針對經營團隊和臨床領導者的具體建議：協調證據、增強供應鏈韌性、整合服務模式，以加速安全推廣並創造長期價值。

產業領導者必須將臨床證據的生成與穩健的營運實務結合，才能將技術潛力轉化為持續的病患獲益和商業性可行性。製造商應優先收集植入登記和核准後監測中嵌入的縱向安全性和生活品質數據，以確保真實世界證據能夠支撐與支付方的對話和增強臨床醫生的信心。同時，策略性供應鏈多元化，包括檢驗的二級供應商和區域生產方案，可以降低貿易政策變化和零件集中度帶來的風險。

我們採用透明、以臨床醫生為導向的調查方法，結合專家訪談、監管審查和同行檢驗證據，以產生可操作的醫療設備和專案見解。

本分析的調查方法融合了定性專家對話、系統性臨床文獻綜述、監管申報文件以及醫療設備性能資料集，旨在構建一個平衡且以實踐為導向的觀點。主要研究內容包括與臨床醫生、外科專案主任、供應鏈經理和醫療設備工程師進行結構化訪談，以揭示現實世界中的限制因素、患者選擇方面的細微差別以及醫療設備生命週期管理方面的考慮。這些第一手見解輔以對同行評審的臨床研究、監管摘要和技術白皮書的反覆審查，以確保技術論點基於檢驗的證據。

總之，我們的綜合分析強調了證據、運作韌性和臨床醫生支持如何共同決定磁浮左心室輔助裝置 (LVAD) 的永續採用及其對患者的影響。

全磁浮左心室輔助裝置融合了技術創新與臨床需求，可望提高血液相容性、減少機械故障模式並改善患者體驗。其成功應用不僅取決於裝置效能，也取決於臨床計畫的準備情況，包括先進的監測、看護者培訓和長期追蹤。隨著生態系統的日趨成熟，成功將取決於嚴謹的真實世界證據、穩健的供應鏈以及能夠降低安全應用障礙的商業性永續服務模式的整合。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 全磁浮左心室輔助裝置市場（依電源分類）

  • 外接電池
  • 商用電源

9. 依患者年齡分類的全磁浮左心室輔助裝置市場

  • 成人版
  • 兒童

第10章 全磁浮左心室輔助裝置市場（依應用分類）

  • 通往復健的橋樑
  • 移植橋樑
  • 最終治療

第11章 全磁浮左心室輔助裝置市場（依最終用戶分類）

  • 心臟中心
  • 醫院

第12章 全磁浮左心室輔助裝置市場（依分銷管道分類）

  • 直銷
  • 透過分銷商銷售

第13章 各地區全磁浮左心室輔助裝置市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 全磁浮左心室輔助裝置市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國全磁浮左心室輔助裝置市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 美國全磁浮左心室輔助裝置市場

第17章 中國全磁浮左心室輔助裝置市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Berlin Heart GmbH
  • BiVACOR Inc.
  • CH Biomedical Co., Ltd.
  • CorWave SA
  • Evaheart Inc.
  • Jarvik Heart Inc.
  • Leviticus Cardio LLC
  • Medtronic plc
  • ReliantHeart Inc.
  • Shenzhen Core Medical Technology Co., Ltd.
  • Suzhou Tongxin Medical Devices Co., Ltd.
  • SynCardia Systems LLC
  • Teleflex Incorporated
Product Code: MRR-867BED9A9E7F

The Fully MagLev Left Ventricular Assist Device Market was valued at USD 1.59 billion in 2025 and is projected to grow to USD 1.78 billion in 2026, with a CAGR of 10.83%, reaching USD 3.27 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.59 billion
Estimated Year [2026] USD 1.78 billion
Forecast Year [2032] USD 3.27 billion
CAGR (%) 10.83%

An authoritative introduction framing the clinical and engineering advances that define fully maglev left ventricular assist devices and their implications for care delivery

The advent of fully magnetically levitated left ventricular assist devices represents a pivotal inflection point in advanced heart failure therapy, merging mechanical engineering precision with clinical imperatives for durability and hemocompatibility. These next-generation pumps minimize mechanical contact, reducing shear stress on blood and lowering the incidence of device-related hemolysis, thrombosis, and adverse neurologic events. Clinicians are increasingly evaluating these systems not only for bridging strategies but also as durable alternatives where transplantation is not immediately feasible.

In parallel, improvements in biocompatible materials, computational fluid dynamics, and sensor-driven controls have improved device responsiveness and safety, enabling more refined patient management pathways. As a result, multidisciplinary teams including cardiac surgeons, heart failure cardiologists, perfusionists, and device engineers are collaborating earlier in the treatment continuum. Consequently, procurement, clinical adoption, and long-term care models must adapt to the operational realities of fully maglev technology, including new requirements for monitoring, power management, and post-market surveillance

A clear exposition of the convergent technological, regulatory, and clinical shifts reshaping adoption, procurement, and long-term management of maglev LVAD therapies

The landscape around fully maglev left ventricular assist devices is shifting rapidly as a result of converging forces in technology, regulation, and clinical practice. Technologically, the integration of advanced magnetic suspension, improved hemocompatible surfaces, and embedded diagnostics has elevated the therapeutic profile of LVADs, enabling longer functional life and lower complication rates. Clinically, patient selection criteria are evolving as heart teams gain confidence in using these systems for both bridge-to-transplant and destination therapy scenarios, thereby expanding candidate pools and redefining long-term care pathways.

Regulatory and reimbursement ecosystems are also in motion; payers and health technology assessors are placing greater emphasis on real-world evidence and quality-of-life outcomes, prompting manufacturers to collect and disclose longitudinal performance metrics. Moreover, supply chain resilience and strategic manufacturing localization are emerging as determinants of program stability. Taken together, these transformative shifts are compelling stakeholders to reassess clinical protocols, investment strategies, and partnership models to capture the full potential of maglev LVADs

An incisive analysis of how 2025 United States tariff changes introduce supply chain, sourcing, and procurement complexity for fully maglev LVAD developers and providers

Recent tariff actions and trade policy adjustments in the United States for 2025 have introduced new variables into device sourcing, component procurement, and cross-border distribution strategies. Manufacturers that rely on globalized supply chains for precision magnets, power electronics, and specialized polymers face increased landed cost variability, which in turn influences decisions on component sourcing, inventory buffers, and manufacturing footprints. These dynamics are prompting device developers to reassess supplier diversification and nearshoring options to protect program timelines and quality standards.

Clinicians and hospital systems are correspondingly adapting purchasing strategies to mitigate procurement risk, emphasizing longer lead-time planning and closer collaboration with vendors on contractual protections. Meanwhile, investors and strategic partners are recalibrating capital allocation for clinical trials and production scale-up to reflect the evolving cost structure. Ultimately, the cumulative impact of tariff changes is less about a single cost figure and more about the strategic realignment they drive across manufacturing, supply security, and clinical deployment pathways

A detailed segmentation-driven insight that explains how application, distribution, patient demographics, power architecture, and end-user profiles determine adoption pathways and program design

Segment-specific dynamics reveal differentiated pathways to adoption and usage patterns across the fully maglev LVAD landscape when examined through established clinical and commercial lenses. Based on Application, market is studied across Bridge To Recovery, Bridge To Transplant, and Destination Therapy; each application imposes distinct device lifecycle expectations, monitoring regimens, and clinical outcome priorities, with bridge scenarios emphasizing short-term reliability and destination therapy emphasizing long-term durability and patient quality of life. Based on Distribution Channel, market is studied across Direct Sales and Distributor Sales; direct sales models facilitate tighter clinical integration and post-implant support, whereas distributor channels extend geographic reach and local service coverage.

Further nuance emerges when considering age demographics and power architectures. Based on Patient Age, market is studied across Adult and Pediatric; pediatric adoption remains constrained by anatomical and growth considerations, driving design adaptations and specialized surgical protocols. Based on Power Source, market is studied across External Battery and Mains Power; energy management strategies, battery life, and charging protocols materially affect outpatient mobility, homecare logistics, and caregiver training. Finally, based on End User, market is studied across Cardiac Centers and Hospitals; high-volume cardiac centers often act as early adopters with integrated heart failure programs, while general hospitals may require bundled support services to safely manage outpatient follow-up and emergency contingencies. Collectively, these segmentation lenses clarify investment priorities, clinical training needs, and commercialization pathways for stakeholders

Comprehensive regional insights that reveal how varying healthcare architectures, reimbursement frameworks, and clinical capabilities shape adoption of maglev LVAD solutions across global territories

Geographic variation shapes clinical practice patterns, regulatory interactions, and commercial deployment for fully maglev LVAD solutions. In the Americas, advanced cardiac programs and consolidated payer systems in certain jurisdictions favor early clinical adoption and the aggregation of long-term outcome data, enabling centers of excellence to iterate on post-implant care models. In contrast, different health system architectures across the Europe, Middle East & Africa region create heterogenous reimbursement pathways, requiring tailored market access strategies that account for national HTA processes, hospital procurement practices, and regional center capabilities.

Across the Asia-Pacific corridor, rising incidence of advanced heart failure, expanding tertiary care capacity, and active local manufacturing initiatives are driving a distinctive adoption trajectory. Patient demographics, surgical training pipelines, and the pace of regulatory harmonization vary significantly between high-income metropolitan centers and emerging regional hubs. Consequently, successful regional strategies blend clinical education, local partnership models, and adaptive pricing and service frameworks to address divergent stakeholder expectations while ensuring safe, high-quality program rollouts

Key company-level insights into how technological leadership, strategic partnerships, and robust post-market capabilities determine competitive advantage in maglev LVAD development

Competitive dynamics in the fully maglev LVAD arena are characterized by deep technology specialization, strategic partnerships, and a premium on post-market evidence generation. Established medical device firms and specialist startups alike prioritize sustained R&D investments in magnetics, biomaterials, and embedded diagnostics to secure long-term device reliability and clinician trust. In parallel, companies are forging collaborations with academic centers, contract manufacturers, and digital health providers to accelerate evidence generation and to integrate remote monitoring into standard care pathways.

Operational capabilities such as manufacturing quality systems, scalability, and regulatory affairs expertise remain decisive differentiators, while aftermarket services including training, warranty support, and outcome tracking underpin commercial success. As a result, organizations that can align clinical validation programs with robust supply chain strategies and clinician-facing service models are most likely to advance adoption. Strategic M&A and selective licensing of core technologies are further mechanisms by which players aim to consolidate capabilities and expand clinical indications over time

Actionable recommendations for executives and clinical leaders to synchronize evidence, supply resilience, and integrated service models that accelerate safe adoption and long-term value

Industry leaders must align clinical evidence generation with resilient operational practices to translate engineering promise into sustained patient benefit and commercial viability. Manufacturers should prioritize longitudinal safety and quality-of-life data collection embedded within implant registries and post-approval studies, ensuring that real-world evidence supports payer dialogues and clinician confidence. At the same time, strategic supply chain diversification, including validated secondary suppliers and localized production options, will mitigate the risk introduced by shifting trade policies and component concentration.

From a commercial perspective, tailored go-to-market strategies that differentiate between high-volume cardiac centers and broader hospital networks will enhance adoption. Investments in clinician education, integrated service bundles, and remote monitoring infrastructure will lower implementation friction and improve patient outcomes. Finally, cross-sector collaborations-spanning academic centers, digital health vendors, and specialty service providers-can accelerate the development of comprehensive care pathways that realize the full clinical and economic value of fully maglev LVAD therapy

A transparent, clinician-oriented research methodology combining expert interviews, regulatory review, and evidence cross-validation to produce actionable device and program insights

The research methodology underpinning this analysis blends qualitative expert engagement with systematic review of clinical literature, regulatory filings, and device performance datasets to generate a balanced, practice-oriented perspective. Primary inputs include structured interviews with clinicians, surgical program directors, supply chain managers, and device engineers, which illuminate real-world operational constraints, patient selection nuances, and device lifecycle management considerations. These firsthand insights are corroborated by an iterative review of peer-reviewed clinical studies, regulatory summaries, and technical white papers to ensure technical assertions are grounded in verifiable evidence.

To ensure robust interpretation, cross-validation steps were employed where emerging themes from interviews were tested against independent clinical registries and device safety communications. Analytical emphasis was placed on device design characteristics, hemocompatibility profiles, post-implant management protocols, and health system readiness. Throughout, care was taken to transparently document assumptions and to prioritize clinical relevance over speculative projections, enabling decision-makers to apply findings directly to program planning and vendor evaluation

A conclusive synthesis underscoring how evidence, operational resilience, and clinician support jointly determine the sustainable adoption and patient impact of maglev LVADs

Fully maglev left ventricular assist devices stand at the intersection of engineering innovation and clinical need, offering a pathway to improved hemocompatibility, fewer mechanical failure modes, and enhanced patient experiences. Adoption will be shaped not only by device performance but equally by the readiness of clinical programs to implement advanced monitoring, caregiver training, and long-term follow-up infrastructures. As the ecosystem matures, success will hinge on the integration of rigorous real-world evidence, resilient supply chains, and commercially viable service models that lower barriers to safe implementation.

Looking ahead, stakeholders that proactively align clinical validation with scalable manufacturing and tailored market access strategies will be best positioned to convert technological promise into sustainable clinical programs. By focusing on evidence, operational resilience, and clinician support, the community can accelerate adoption in a way that prioritizes patient outcomes while addressing the practical complexities of device deployment and continuity of care

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fully MagLev Left Ventricular Assist Device Market, by Power Source

  • 8.1. External Battery
  • 8.2. Mains Power

9. Fully MagLev Left Ventricular Assist Device Market, by Patient Age

  • 9.1. Adult
  • 9.2. Pediatric

10. Fully MagLev Left Ventricular Assist Device Market, by Application

  • 10.1. Bridge To Recovery
  • 10.2. Bridge To Transplant
  • 10.3. Destination Therapy

11. Fully MagLev Left Ventricular Assist Device Market, by End User

  • 11.1. Cardiac Centers
  • 11.2. Hospitals

12. Fully MagLev Left Ventricular Assist Device Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributor Sales

13. Fully MagLev Left Ventricular Assist Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Fully MagLev Left Ventricular Assist Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Fully MagLev Left Ventricular Assist Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Fully MagLev Left Ventricular Assist Device Market

17. China Fully MagLev Left Ventricular Assist Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Berlin Heart GmbH
  • 18.7. BiVACOR Inc.
  • 18.8. CH Biomedical Co., Ltd.
  • 18.9. CorWave SA
  • 18.10. Evaheart Inc.
  • 18.11. Jarvik Heart Inc.
  • 18.12. Leviticus Cardio LLC
  • 18.13. Medtronic plc
  • 18.14. ReliantHeart Inc.
  • 18.15. Shenzhen Core Medical Technology Co., Ltd.
  • 18.16. Suzhou Tongxin Medical Devices Co., Ltd.
  • 18.17. SynCardia Systems LLC
  • 18.18. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY EXTERNAL BATTERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY MAINS POWER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO RECOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY BRIDGE TO TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DESTINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTOR SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 73. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 79. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 98. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GCC FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. G7 FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 122. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. NATO FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY POWER SOURCE, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA FULLY MAGLEV LEFT VENTRICULAR ASSIST DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)